Pansclerotic Morphea Patient

Existing code adjustment:

Separate into 3 groups (not 2 as shown): control, morphea\_lesional and morphea\_nonlesional

Reduce annotations: Fibroblasts, Keratinocytes, CD4cells, CD8cells, Myeloid cells, B cells, Endothelial cells, Red blood cells. Melanocytes, SMA and pericytes

Perform DGE expression comparison between the groups of cells and Normalised DGE distance (or something in this kind of way)

Check endothelial cells (and then later keratinocytes if possible): I have found there is pSTAT3 activation when using IF in this patient type, with strong Th17 immune cell domination surrounding them, pSTAT3 changes found in my sample in lesional area as well as non-lesional area surrounding it

Problem of the dataset: non\_lesional are not defined how far is it from the lesion

Patient was (potentially) treated with corticosteroids and TOCILIZUMAB (IL-6R inhibitor), did it affect some pathways???? Also including pSTAT3????